KD2308

KD2308 is a generic small molecule drug candidate developed by Kyungdong Pharmaceutical for the treatment of gastrointestinal disorders. It is a generic version of vonoprazan, a potassium-competitive acid blocker (P-CAB). Vonoprazan functions by competitively inhibiting the potassium-binding site of the gastric H+,K+-ATPase (proton pump) in the parietal cells of the stomach. This mechanism provides rapid, potent, and sustained suppression of gastric acid secretion, which is beneficial for conditions such as gastroesophageal reflux disease (GERD) and peptic ulcers. Unlike traditional proton pump inhibitors (PPIs), KD2308 does not require acid activation and is stable in acidic environments. The drug is currently in Phase 1 development, specifically undergoing bioequivalence studies to support regulatory approval as a generic alternative to the reference listed drug.

Other names

vonoprazan generic